Allergic Bronchopulmonary Aspergillosis

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

CFTR, IL5, SFTPA2, RBM45, MBL2, HLA-DRB1, SFTPA1, FOXP3, POSTN, QPCT, MBL3P, CARD9, TLR9, TNF, NLRP3, COPD, SLC9A6, AGA, SOD2, PPBP, ALOX15, IL15, IL10, CXCL8, IL4, IFNG, HLA-DQB1, FLNC, CCT, CAT

CFTR, IL5, SFTPA2, RBM45, MBL2, HLA-DRB1, SFTPA1, FOXP3, POSTN, QPCT, MBL3P, CARD9, TLR9, TNF, NLRP3, COPD, SLC9A6, AGA, SOD2, PPBP, ALOX15, IL15, IL10, CXCL8, IL4, IFNG, HLA-DQB1, FLNC, CCT, CAT, MMP9

Drugs

—

Interested in hearing about new therapies?

Allergic bronchopulmonary aspergillosis is an allergic lung reaction to a type of fungus (Aspergillus fumigatus). Symptoms vary, but may include wheezing, bronchial hyperreactivity, hemoptysis, productive cough, low-grade fever, malaise, and weight loss. It is more common in people who have asthma or cystic fibrosis. The recommended treatment for allergic bronchopulmonary aspergillosis is itraconazole, a prescription antifungal medication. Oral corticosteroids, like prednisone, may also be helpful. The clinical course of allergic bronchopulmonary aspergillosis is variable. Many people with this condition can be stabilized for long periods when treated. However, only about 50% of patients achieve long-lasting remission and many require recurrent courses of treatment.